GlassScriptPhysician profile
Michael A Barnett
NPI 1831308725
$1,085.66
in general payments reported to CMS, 2019-2025
16 companies · $15.31 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.99 · 2020: $210 · 2021: $142 · 2022: $216 · 2023: $336 · 2024: $103 · 2025: $15.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $175.57 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $168.97 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $149.55 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $142.20 | 2023-2024 | Onpattro |
| Impulse Dynamics (USA) INC. | $90.04 | 2022-2023 | Optimizer |
| Cardiva Medical, INC. | $81.80 | 2022 | |
| Amgen INC. | $50.07 | 2020-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.29 | 2019-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.22 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $30.00 | 2020 | |
| Biotronik INC. | $26.87 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.80 | 2023 | Brilinta |
| Abbott Laboratories | $18.03 | 2021 | |
| Boston Scientific Corporation | $17.51 | 2023 | |
| Chiesi USA, INC. | $15.31 | 2025 | Kengreal |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.